LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Strona główna・Stock List・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Closed

SectorHealthcare

14.28 -1.92

Buy Sell

Overview

Share price change

24h

Current

Min

14.14

Max

14.39

Key metrics
By Trading Economics
Income	179M 211M
Sales	3.6M 77M
P/E Sector Avg	7.034 57.05
Profit margin	273.354
Employees	128
EBITDA	10M 47M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+9.59% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-19M 1.9B
Previous open	16.2
Previous close	14.28

News Sentiment

By Acuity

20%

80%

47 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

8.1 / 8.21 Support & Resistance

Aurinia Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 mar 2026, 00:29 UTC

Acquisitions, Mergers, Takeovers

13D Filings -- Barrons.com

3 lis 2025, 09:49 UTC

Hot Stocks

Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir -- WSJ

Peer Comparison

Price change

Aurinia Pharmaceuticals Inc Forecast

Price Target

By TipRanks

9.59% upside

12 Months Forecast

Average 16 USD 9.59%

High 17 USD

Low 15 USD

Based on 4 Wall Street analysts offering 12 month price targets forAurinia Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Aurinia Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

8.1 / 8.21Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Sentiment

By Acuity

47 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.